echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Vaxzevria targets Omicron variant with preliminary positive data

    Vaxzevria targets Omicron variant with preliminary positive data

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, AstraZeneca reported data from a trial of its vaccine Vaxzevria against a variant of Omicron
    .

    Results from the immunogenicity and safety trial D7220C00001 showed that the vaccine produced higher antibody responses to the Omicron variant, as well as other variants, including Beta, Delta, Alpha and Gamma, according to Reuters
    .

    immunity

    AstraZeneca reported an increase in responses in people who had previously been vaccinated with Vaxzevria or the mRNA vaccine
    .
    They added that, given the current need for booster doses, they will submit these data to global regulators

    .

    AstraZeneca developed Vaxzevria with researchers at Oxford University, and lab studies last month found that three doses of Vaxzevria were effective against Omicron
    .

    Vaxzevria consists of a virus (adenovirus) that has been modified to contain the genes that make the SARS-CoV-2 virus
    .
    Once injected, the vaccine delivers the SARS-CoV-2 gene into cells and into the body

    .
    Cells will use this gene to produce the spike protein

    .
    The individual's immune system then recognizes this protein as foreign and produces antibodies in response, activating T cells to attack it

    .

    In December 2021, a major UK trial found that AstraZeneca's vaccine increased antibody levels when given as a booster after an initial vaccination with its own vaccine or a vaccine based on mRNA technology
    .
    Still, the study concluded that mRNA vaccines made by Pfizer and Moderna had the greatest boost to antibodies at booster doses

    .
    Andrew Pollard, head of the Oxford Vaccine Group, commented: "These important studies show that a third dose of Vaxzevria strongly enhances immunity to COVID-19
    following two initial doses of the same vaccine, or following either an mRNA or an inactivated vaccine.
    force" .

    "These important studies show that following two initial doses of the same vaccine, or following an mRNA or inactivated vaccine, a third dose of Vaxzevria strongly boosts immunity against COVID-19
    .
    "
    "These important studies show that following two initial doses of the same vaccine, or following an mRNA or inactivated vaccine, a third dose of Vaxzevria strongly boosts immunity against COVID-19
    .
    "
    COVID-19

     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https://

    Leave a comment here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.